- Home
- NXGL vs LSB Comparison
NXGL vs LSB Comparison
Compare NXGL & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- LSB
- Stock Information
- Founded
- NXGL 1997
- LSB 2002
- Country
- NXGL United States
- LSB China
- Employees
- NXGL N/A
- LSB N/A
- Industry
- NXGL Medical/Dental Instruments
- LSB
- Sector
- NXGL Health Care
- LSB
- Exchange
- NXGL Nasdaq
- LSB NYSE
- Market Cap
- NXGL 19.7M
- LSB 22.3M
- IPO Year
- NXGL 2021
- LSB N/A
- Fundamental
- Price
- NXGL $2.65
- LSB N/A
- Analyst Decision
- NXGL
- LSB
- Analyst Count
- NXGL 0
- LSB 0
- Target Price
- NXGL N/A
- LSB N/A
- AVG Volume (30 Days)
- NXGL 41.5K
- LSB 24.1K
- Earning Date
- NXGL 08-13-2025
- LSB 07-15-2025
- Dividend Yield
- NXGL N/A
- LSB N/A
- EPS Growth
- NXGL N/A
- LSB N/A
- EPS
- NXGL N/A
- LSB N/A
- Revenue
- NXGL $10,228,000.00
- LSB $79,415,311.00
- Revenue This Year
- NXGL $52.35
- LSB $39.33
- Revenue Next Year
- NXGL $42.38
- LSB $75.61
- P/E Ratio
- NXGL N/A
- LSB N/A
- Revenue Growth
- NXGL 116.01
- LSB N/A
- 52 Week Low
- NXGL $1.95
- LSB $0.36
- 52 Week High
- NXGL $5.10
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- NXGL 60.17
- LSB 45.97
- Support Level
- NXGL $2.31
- LSB $0.89
- Resistance Level
- NXGL $2.78
- LSB $1.12
- Average True Range (ATR)
- NXGL 0.20
- LSB 0.07
- MACD
- NXGL 0.04
- LSB 0.02
- Stochastic Oscillator
- NXGL 74.53
- LSB 45.70
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.